InfoBionic Announces $8 Million Series B-1 Financing Led By Safeguard Scientifics

Share Article

Additional funding by existing shareholders supports digital health company’s product development and commercialization strategy

News Image
With continued support from our financial partners, we believe that we have a unique opportunity to commercialize our platform and, in turn, revolutionize how chronic diseases are detected, monitored and treated.

InfoBionic, Inc., an emerging digital health company focused on creating superior patient monitoring solutions for chronic disease management, today announced an $8 million Series B-1 financing led by Safeguard Scientifics (NYSE:SFE) with participation from existing shareholders Excel Venture Management; Zaffre Investments, a subsidiary of Blue Cross Blue Shield of Massachusetts; and various angels. Proceeds from the funding will support InfoBionic’s ability to capitalize on the significant opportunity in the cardiac arrhythmia market and commercialize its MoMe® Kardia system, a remote patient monitoring platform for cardiac arrhythmia detection.

“We’ve seen first-hand the need for innovation amongst complex, fragmented systems that have been used in arrhythmia detection and monitoring for years,” said Nancy Briefs, President, CEO and Co-Founder of InfoBionic. “As a result, the InfoBionic team designed the transformative MoMe® Kardia platform. With continued support from our financial partners, we believe that we have a unique opportunity to commercialize our platform and, in turn, revolutionize how chronic diseases are detected, monitored and treated.”

InfoBionic’s MoMe® Kardia 3-in-1, cloud-based remote patient monitoring platform—the first and only of its kind—delivers on-demand, actionable monitoring data and analytics for Holter, Event, and MCT directly to physicians. MoMe Kardia streams continuous electrocardiogram, respiration and motion data to the cloud for analysis and delivers automated reporting to any mobile device, tablet or web-based portal where physicians can access and interact with the data they need, in the detail they want—anytime, anywhere. This paradigm-shifting system puts physicians in the driver’s seat, giving them the power to directly control the clinical, analytical, and economic aspects that streamline patient monitoring management, improve analysis time, enhance the patient experience, and ultimately drive better outcomes.

About InfoBionic
InfoBionic is an emerging digital health company focused on creating superior patient monitoring solutions for chronic disease management with an initial market focus on cardiac arrhythmias. InfoBionic’s MoMe® Kardia system will empower physicians with control to transform the efficiency with which they manage cardiac arrhythmia detection and monitoring processes for their patients. For more information please visit http://www.infobionic.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Heather Hunter

+1 (610) 975-4923
Email >
Visit website